Overview of Lysotossil

This foundational section provides an authoritative overview of the identity and general therapeutic purpose of the medicine Lysotossil.

Property	Description
Active ingredient	Cloperastine
Form	Syrup, solution, tablets, dragees, granules
Pharmacological class	Non-opioid antitussive agent
Common use	Symptomatic relief of non-productive (dry) cough
Origin	Synthetic compound (Diphenylmethane class)

What Type of Medicine is Lysotossil (Cloperastine)?

Lysotossil is a pharmaceutical preparation classified as a non-opioid antitussive agent, designed for cough suppression. The active ingredient is Cloperastine, a synthesized compound identified by the ATC code R05DB21. Cloperastine belongs to the diphenylmethane chemical class. It acts as a centrally-acting medicine, and its non-opioid nature is intended to reduce the urge to cough without the dependency risks associated with narcotic suppressants such as codeine. Lysotossil is defined as a single-ingredient product, or monotherapy, offering focused relief.

Composition and Available Forms of Lysotossil

The composition of Lysotossil is defined by the sole active substance, Cloperastine, typically supplied as either the Cloperastine Hydrochloride or Cloperastine Fendizoate salt forms. The Fendizoate salt form is frequently used to formulate the palatable syrup or drinkable solution, which is a factor often preferred for children. This preparation is available in multiple dosage forms for oral administration, including liquid forms, tablets, dragees, and granules.

The General Purpose of Lysotossil

The general purpose of Lysotossil is to achieve effective cough suppression by modulating the cough center in the brain, offering symptomatic relief specifically for the non-productive cough. The central action reduces the involuntary frequency and intensity of the cough reflex signal. Because it targets the core mechanism of the impulse, the medicine provides focused relief from the discomfort caused by frequent, hacking dry coughs that do not produce phlegm.

Regulatory References

What side effects are possible with Lysotossil?

Possible side effects and safety information

The safety profile for Lysotossil (Cloperastine) is structured around officially documented adverse reactions and specific regulatory constraints outlined in government prescribing information.

Adverse Reaction Classifications

Adverse reactions are officially categorized by the physiological systems affected, and their frequency is classified according to regulatory standards.

Classification	Representative Adverse Reaction	System-Organ Class
Uncommon	Somnolence, Dry mouth, Dizziness, Tremor, Fatigue	Nervous System / Gastrointestinal
Not Known	Allergic reactions, Urticaria, Anaphylaxis	Immune System / Skin

Reactions classified as Uncommon are typically observed in less than 1 in 100 individuals. Those with a frequency of Not Known are generally derived from post-marketing surveillance and cannot be reliably estimated from available data.

Serious Reactions and Safety Constraints

The most clinically significant reaction noted in regulatory documents is Anaphylaxis, which is a potentially serious, acute hypersensitivity response classified under the Not Known frequency band.

Official labeling defines specific safety constraints:

Hypersensitivity: The medicine is strictly contraindicated in individuals with a known sensitivity to the active substance, Cloperastine, or any of the formulation’s excipients.
Concomitant Use: Caution is required when combining Lysotossil with other CNS depressant substances (e.g., alcohol, sedatives), as this may increase the effect of somnolence.
Population Safety: Specific caution is advised in patients with pre-existing severe hepatic impairment and severe renal impairment. Age restrictions also apply to the use of some formulations in pediatric populations.

Overdose and Emergency Response

Overdose and When to Seek Help

Overexposure to Lysotossil (Cloperastine) is a potentially severe scenario that requires immediate emergency medical attention. The official regulatory prescribing information documents a range of clinical manifestations, primarily affecting the Central Nervous System (CNS). Documented signs of overdosage include drowsiness and sedation, as well as paradoxical CNS excitation presenting as tremors, psychomotor excitement, and, in severe cases, convulsions. Other noted manifestations are severe anticholinergic effects and mental status changes, such as toxic psychosis and hallucinations.

Life-threatening outcomes officially documented in the overdose profile involve the Respiratory System (e.g., respiratory depression and apnea) and the Cardiovascular System (e.g., cardiovascular collapse). Due to the risk of such systemic compromise, regulators mandate that immediate medical help must be sought following any suspected overexposure.

Official guidance states that no specific antidote is known for Cloperastine overdosage. Management is therefore limited to symptomatic and supportive treatment, including the maintenance of vital functions, and may involve procedures such as gastric lavage or the administration of activated charcoal. Furthermore, the regulatory profile highlights a population-specific concern, noting that children and the elderly are particularly susceptible to CNS excitatory effects. Hospital monitoring is required for continuous observation of potential symptom escalation.

Therapeutic Uses of Lysotossil

Lysotossil contains cloperastine or cloperastine fendizoate, an agent applied in addressing symptoms related to heightened physiological activity that manifest as a cough.

Lysotossil Main Uses and Benefits

The primary use of Lysotossil is for the symptomatic treatment of bothersome non-productive cough in adults and children over a certain age, which falls under conditions characterized by periods of heightened symptoms. This medication is relevant for managing symptoms that interfere with daily comfort and can become disruptive, particularly during periods of rest. Lysotossil is commonly used to help with a dry cough that does not produce phlegm.

The active ingredient, cloperastine, is classified as an antitussive, and its use is applicable across domains where additional symptomatic support is needed. It helps address symptom clusters that may become intense or disruptive, such as a dry cough or an irritative cough that creates noticeable physiological strain. It supports patients during difficult episodes by easing distress and assists with maintaining functional stability when symptoms interfere with routine activities. This provides support that helps ease the overall symptom burden. One clinical context where this medication is often used is during phases when symptoms become more noticeable, providing short-term symptomatic assistance.

“This medication is applied in scenarios where additional management of discomfort is required for these episodic manifestations.”

Quick Fact: Provides supportive relief for Dry and Irritative Cough.

Regulatory References

national health regulator’s guidance on the product

Eligibility and Restrictions for Use

Who can and cannot use Lysotossil?

Lysotossil (Cloperastine) eligibility is defined by official regulatory authorities through a set of strict contraindications and use restrictions based on age and health status.

Populations Excluded from Use (Contraindications)

Lysotossil is formally contraindicated in several high-risk populations. Individuals must not use the medicine if they have a known hypersensitivity to Cloperastine or its excipients. Use is also prohibited in patients taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing them. Furthermore, the medicine is contraindicated for children under 2 years of age and for women who are pregnant or breastfeeding (lactating). Official labeling also prohibits use in patients with conditions associated with reduced mucociliary clearance.

Age and Condition-Based Restrictions

Pediatric Use: The medicine is generally not recommended for children between 2 and 12 years of age.
Older Adults: Use in this population is permitted but requires explicit caution.
Physiological Restrictions: Patients with severe hepatic or renal impairment must use the medicine with caution. Caution is also required for individuals with specific comorbidities, including glaucoma and prostatic hypertrophy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Lysotossil (Cloperastine) is defined by its potential for pharmacodynamic interactions with agents that affect the central nervous system (CNS) or possess anticholinergic properties.

Formal Regulatory Restrictions

Co-administration with MAO Inhibitors (Monoamine oxidase inhibitors) is formally listed as a contraindication in prescribing information.

Documented Pharmacodynamic Interactions

Interacting Substance Category	Interaction Pattern	Restriction/Outcome
CNS Depressors (e.g., Anxiolytics, Barbiturates, Narcotics, Alcohol)	Additive CNS effects	Enhanced sedative effect is documented.
Anticholinergic Drugs (e.g., Tricyclic antidepressants, Neuroleptics)	Reciprocal effect enhancement	Can reciprocally increase anticholinergic effects.
Expectorants / Mucolytic Drugs	Physiological interference	Risk of pulmonary obstruction due to inhibited cough reflex.

Mechanism of Action

How Lysotossil Works

Lysotossil exerts its action through two distinct mechanisms that modulate airway physiology. The primary function involves direct chemical mucolysis. The active compound functions as a reducing agent by targeting and cleaving the disulfide bonds ( S-S) within mucin glycoproteins. This interaction physically depolymerizes the complex mucus structure, leading to a reduction in its viscosity and elasticity. This modification influences the mucociliary transport system, supporting enhanced clearance dynamics.

Simultaneously, the drug engages in dual cellular modulation. It acts as an allosteric modulator to suppress the NF-kappa B signaling pathway, limiting the cellular production of pro-inflammatory mediators. It also serves as a direct antioxidant scavenger against damaging Reactive Oxygen Species ( ROS), thereby reducing oxidative impact on epithelial structures. These combined molecular actions lead to predictable physiological adjustments that modulate system homeostasis within the respiratory lining. This mechanistic synergy influences the integrity and function of the airway system.

Dosage and Administration Information

How to Use Lysotossil: Administration Guidelines

Lysotossil (Cloperastine) is administered exclusively through the oral route for the standardized, short-term management of symptoms. The use of this medicine is structured by defined dosage ranges, frequency patterns, and administration constraints.

Dosage and Schedule

Instruction Domain	Detail
Route of Administration	Oral only (by mouth).
Adult Unit Dose	Typically 10 mg to 20 mg per dose.
Adult Total Daily Dose	Total dose should not exceed 60 mg or 80 mg daily, taken in divided doses.
Frequency Pattern	Administered multiple times daily, typically three to four times per day (TID to QID).
Duration Limit	Intended for short-term symptomatic use, usually limited to a maximum of 5 to 7 days.

Administration Requirements

Administration depends on the specific form of the medicine. Solid forms, such as tablets or dragees, are generally swallowed whole with water. When using the liquid oral solution or syrup, accurate delivery is required; the dose must be measured using a calibrated device, such as a measuring cup or syringe, to prevent errors in quantity. Lysotossil is typically taken without regard to meal times, as explicit administration timing relative to food is not universally required.

Population-Specific Use

Specific pediatric dosing guidelines require careful calculation based on the child's age or body weight. The administration of Lysotossil is restricted to children over a minimum age, which varies (e.g., 2 or 6 years old) based on the specific formulation and applicable guidelines. If a dose is missed, it is generally advised to skip the forgotten dose and resume the regular schedule at the next scheduled time; a double dose must not be taken.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lysotossil

Evidence for use in Chronic Refractory Cough

Lysotossil was studied for chronic refractory cough, a condition characterized by fluctuating or episodic manifestations that was evaluated following other therapies. Research included short-term, 12-week Randomized Controlled Trials (RCTs). These studies were conducted during periods of increased symptom activity and applied in studies examining patient-reported experiences. The patient populations included adults whose long-lasting cough was evaluated following other therapies.

In these trials, researchers monitored several key measures. The primary focus was evaluated in studies tracking changes in cough frequency over 24 hours using objective acoustic devices. These studies monitored outcomes compared to a control group (such as a placebo or a comparator agent). Additionally, research examined patient-reported outcomes describing perceived discomfort. Studies reported measurements of change in cough frequency over the short study period. Research provides insight into changes measured during the study period for both the objective cough count and the reported impact on quality of life.

Key limitations were noted in the study reports. The follow-up durations were primarily limited to 12 weeks. Long-term effects are not fully established, as the duration of observation beyond one year is not well characterized.

Evidence for use in Post-Infectious Bronchial Hyperreactivity

Lysotossil was evaluated in settings related to post-infectious bronchial hyperreactivity. Research in this area primarily used small-scale pilot studies and observational cohort studies. The studies focused on adults and adolescents who showed signs of airway sensitivity after an infection. Researchers explored outcomes describing episodic or acute changes, such as the time taken for symptoms to resolve completely. The precise time frame for study enrollment following the initial infection has not been a primary focus of RCTs.

Evidence in Special Populations and Uncertainties

Research was studied for some special populations, including older adults (those aged 65 and above), to assess how the measurements and outcomes compare to the general adult population. For other groups, such as children, data are still emerging or remain insufficient.

Evidence quality varies across studies. The sample sizes were modest in the studies conducted for post-infectious bronchial hyperreactivity and bronchiectasis. The available evidence primarily provides insight into short-term changes, and the long-term effects are not fully established.

Frequently Asked Questions (FAQ)

Common questions about Lysotossil (FAQ)

Q: How often do people generally take Lysotossil?

A: Lysotossil is typically taken multiple times daily, commonly three to four times per day (TID to QID). When liquid forms (syrup or solution) are used, official administration guidance indicates that the dose should be accurately measured using a calibrated device, such as a measuring cup or syringe, to help prevent errors in quantity.

Q: Is it normal to feel tired or dizzy after taking Lysotossil?

A: Official product information documents somnolence (drowsiness) and dizziness as potential adverse reactions. These effects are generally classified as uncommon, meaning they are observed in less than 1 out of 100 people who use the medicine.

Q: Can Lysotossil cause stomach upset or nausea?

A: Adverse reactions affecting the gastrointestinal system, which may include mild stomach upset or nausea, are officially documented. These reported effects are typically categorized as uncommon or are noted from post-marketing surveillance where the exact frequency is not known.

Q: Are there any widely known common side effects of Lysotossil?

A: Official safety data does not categorize any adverse reaction as common (affecting more than 1 in 100 people) based on regulatory standards. The most frequently observed reactions are classified as uncommon (occurring in less than 1 in 100 people).

Q: Can older adults use Lysotossil?

A: The use of Lysotossil in older adults (those aged 65 and above) is addressed in official guidelines. However, regulatory texts specify that the medicine must be used with explicit caution in this population.

Q: Does Lysotossil affect the ability to drive or operate machinery?

A: Due to the potential for central nervous system side effects, such as somnolence (drowsiness) and dizziness, regulatory documentation advises that caution is required when engaging in activities that demand mental alertness, such as driving or operating machinery.

Q: Is Lysotossil generally suitable for children?

A: Official labeling defines specific age restrictions for use. Lysotossil is contraindicated (prohibited) for children under 2 years of age. It is generally not recommended for children between 2 and 12 years of age, depending on the specific product formulation and regional regulatory guidance.

Q: Is Lysotossil the same type of medicine as [similar common drug name]?

A: Lysotossil is officially classified as a non-opioid antitussive agent, meaning it works to suppress cough without using an opioid compound. Its active ingredient is Cloperastine, which differentiates it from many other chemical types of cough medicines.

Q: Does Lysotossil contain [common allergen/ingredient, e.g., aspirin or gluten]?

A: Lysotossil contains the active ingredient Cloperastine plus various non-active ingredients, known as excipients, that differ by dosage form (tablet, syrup, etc.). The complete list of excipients is available in the official package insert, which may include substances like sucrose or specific preservatives.

Q: What is the typical timeframe before noticing the effect of Lysotossil?

A: Clinical studies often referenced in regulatory reviews report that the onset of action (the beginning of the effect) occurs approximately 20 to 30 minutes after taking the oral dose. The typical duration of the effect for a single dose is reported to be about 3 to 4 hours.

Q: Is Lysotossil known to be habit-forming or addictive?

A: Regulatory and pharmacological classifications define Lysotossil as a non-opioid antitussive agent. It is described in official documentation as having no documented potential for addiction or habit-forming effects.

Q: What should I do if I think I am experiencing an interaction with Lysotossil?

A: Official guidance indicates that if a person has concerns about a potential interaction or experiences an unexpected or adverse effect, contacting a doctor, pharmacist, or nurse immediately is appropriate.

Q: Is Lysotossil available over the counter, or is it prescription only?

A: The official classification of Lysotossil varies by jurisdiction. In many regions, the medicine is regulated as a non-prescription product available for purchase in a pharmacy. In other areas, it may require a prescription.

Q: Are there any lifestyle or diet changes often mentioned alongside Lysotossil use?

A: Official interaction warnings explicitly highlight that the consumption of alcohol may enhance the sedative effects of Lysotossil. There are no other common, official lifestyle or diet restrictions mandated.

Q: What are the signs of an overdose of Lysotossil?

A: Regulatory documents refer patients to immediately contact a doctor, pharmacist, or a certified Poison Control Center in cases of suspected overdose. Symptoms of overdose generally relate to enhanced central nervous system effects, such as deep drowsiness, confusion, or tremor.

Q: What is the half-life of Lysotossil as described in technical documents?

A: Pharmacokinetic data in regulatory documents provides the half-life of Cloperastine. This value indicates the time required for the concentration of the medicine in the body to decrease by half, and this data is referenced in the official prescribing information.

Q: Is Lysotossil a new medicine or has it been around for a long time?

A: Lysotossil has been available for a significant period. The active ingredient, Cloperastine, was first introduced clinically in Japan in 1972 and subsequently characterized in many European countries.

Q: What is the shelf life of Lysotossil?

A: Official product labeling provides the expiry date which determines the maximum allowed time for use. The shelf life after the product is first opened (specifically for multi-dose liquid forms) is detailed in the package insert for that particular formulation.

Q: Does taking Lysotossil require any special monitoring or testing?

A: Official regulatory documents do not state a requirement for routine, general laboratory monitoring or testing (such as routine blood tests) simply for the use of Lysotossil. Special precautions are noted for patients with pre-existing health conditions like severe kidney or liver impairment.

Q: Is the mechanism of action of Lysotossil fully understood in official sources?

A: Official pharmacological documents describe the primary actions, which include a central antitussive effect. However, research literature cited in regulatory reviews suggests that the full and complex mechanism involving all biological targets is still under scientific study.

Q: What are the common mistakes people make when using Lysotossil?

A: Regulatory warnings and patient instructions often highlight that common mistakes include using the medicine for longer than the recommended short-term duration limit and failure to use a calibrated device to accurately measure liquid forms.

How should Lysotossil be stored and disposed of?

How to Store and Dispose of Lysotossil

Official regulatory guidance dictates specific conditions to maintain the stability and safety of Lysotossil (Cloperastine).

Storage Conditions

The medicine should be stored at room temperature, generally not exceeding 30 C for liquid forms, and must be kept in a dry place protected from light and moisture. The product should be stored in its original container with the cap or closure kept tightly closed.

To prevent accidental ingestion, a mandatory instruction is to keep this medicine out of the sight and reach of children and pets.

Disposal Instructions

Do not use the medicine past the expiry date listed on the packaging. Unused or expired Lysotossil must not be disposed of via wastewater or household waste unless local regulations specifically instruct otherwise. Medicines should be disposed of by taking them to an authorized medicine collection point, such as a pharmacy take-back program, to ensure compliance with pharmaceutical waste rules.

Lysotossil